- Market Capitalization, $K 1,103,387
- Shares Outstanding, K 38,553
- Annual Sales, $ 19,790 K
- Annual Income, $ -95,540 K
- 60-Month Beta 1.23
- Price/Sales 53.93
- Price/Cash Flow N/A
- Price/Book 2.90
|Period||Period Low||Period High||Performance|
| || |
+0.50 (+1.78%)since 11/02/22
| || |
+0.29 (+1.02%)since 09/02/22
| || |
-18.40 (-39.13%)since 12/02/21
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 2.50% and 46.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.
BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.
The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.
The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
|Morphic Holding Inc|
|Virtus Lifesci Biotech Clinical Trials ETF|
|S&P Biotech SPDR|
|Principal Healthcare Innovators Index|
|S&P Biotech Bull 3X Direxion|
|Invesco Nasdaq Biotechnology ETF|
|3rd Resistance Point||31.24|
|2nd Resistance Point||30.01|
|1st Resistance Point||29.31|
|1st Support Level||27.39|
|2nd Support Level||26.16|
|3rd Support Level||25.46|